Support Care Cancer:运动康复对接受化疗放疗的头颈部癌症患者功能能力和生活质量的影响

2020-06-22 MedSci原创 MedSci原创

疲劳、功能下降、生活质量受损是化疗放疗(CRT)最常见的不良后果。头颈部癌症(HNC)在全球范围内影响了50多万人,其治疗对患者造成了沉重的伤害,常常影响到他们的语言、吞咽和呼吸功能,因此他们常常会出

疲劳、功能下降、生活质量受损是化疗放疗(CRT)最常见的不良后果。头颈部癌症(HNC)在全球范围内影响了50多万人,其治疗对患者造成了沉重的伤害,常常影响到他们的语言、吞咽和呼吸功能,因此他们常常会出现疲劳、抑郁和身体不活动。本研究旨在评价基于运动的康复治疗对CRT的HNC患者的功能能力、生活质量、疲劳、血红蛋白和血小板计数的效果。

 

研究对148名接受CRT的头颈癌患者进行随机分组,评价运动对6分钟步行测试测量的功能能力、医疗结果调查短表36 v2问卷测量的生活质量、NCCN(0-10)量表测量的疲劳、血红蛋白和血小板的效果。对照组接受了标准的体力活动建议,而运动组则接受了为期11周的有氧运动和主动阻力运动的结构化运动计划。

 

结果显示,运动组的功能能力(p<0.001)、生活质量(p<0.001)和预防疲劳恶化(p<0.001)均有显著改善。血液参数在对照组和运动组之间未见显著差异。

 

综上所述,该研究结果表明,对接受CRT的HNC患者进行为期11周的结构化运动计划有助于提高他们的功能能力和生活质量。同时也防止了运动组疲劳程度的恶化。

 

原始出处:

 

Stephen Rajan Samuel, Arun G Maiya, et al., Effectiveness of Exercise-Based Rehabilitation on Functional Capacity and Quality of Life in Head and Neck Cancer Patients Receiving Chemo-Radiotherapy.Support Care Cancer. 2019 Oct;27(10):3913-3920. doi: 10.1007/s00520-019-04750-z.  

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1674711, encodeId=fecf16e47113a, content=<a href='/topic/show?id=b1644442913' target=_blank style='color:#2F92EE;'>#头颈部癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44429, encryptionId=b1644442913, topicName=头颈部癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=039a27091165, createdName=wangtianj2016@, createdTime=Mon Apr 19 09:18:36 CST 2021, time=2021-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795207, encodeId=a1411e952073b, content=<a href='/topic/show?id=5cd1169138f' target=_blank style='color:#2F92EE;'>#support#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16913, encryptionId=5cd1169138f, topicName=support)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Fri Feb 05 12:18:36 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289683, encodeId=18a612896833b, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Jun 24 06:18:36 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491866, encodeId=2118149186641, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Wed Jun 24 06:18:36 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589833, encodeId=3e001589833d6, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Wed Jun 24 06:18:36 CST 2020, time=2020-06-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1674711, encodeId=fecf16e47113a, content=<a href='/topic/show?id=b1644442913' target=_blank style='color:#2F92EE;'>#头颈部癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44429, encryptionId=b1644442913, topicName=头颈部癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=039a27091165, createdName=wangtianj2016@, createdTime=Mon Apr 19 09:18:36 CST 2021, time=2021-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795207, encodeId=a1411e952073b, content=<a href='/topic/show?id=5cd1169138f' target=_blank style='color:#2F92EE;'>#support#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16913, encryptionId=5cd1169138f, topicName=support)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Fri Feb 05 12:18:36 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289683, encodeId=18a612896833b, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Jun 24 06:18:36 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491866, encodeId=2118149186641, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Wed Jun 24 06:18:36 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589833, encodeId=3e001589833d6, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Wed Jun 24 06:18:36 CST 2020, time=2020-06-24, status=1, ipAttribution=)]
    2021-02-05 wetgdt
  3. [GetPortalCommentsPageByObjectIdResponse(id=1674711, encodeId=fecf16e47113a, content=<a href='/topic/show?id=b1644442913' target=_blank style='color:#2F92EE;'>#头颈部癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44429, encryptionId=b1644442913, topicName=头颈部癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=039a27091165, createdName=wangtianj2016@, createdTime=Mon Apr 19 09:18:36 CST 2021, time=2021-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795207, encodeId=a1411e952073b, content=<a href='/topic/show?id=5cd1169138f' target=_blank style='color:#2F92EE;'>#support#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16913, encryptionId=5cd1169138f, topicName=support)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Fri Feb 05 12:18:36 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289683, encodeId=18a612896833b, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Jun 24 06:18:36 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491866, encodeId=2118149186641, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Wed Jun 24 06:18:36 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589833, encodeId=3e001589833d6, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Wed Jun 24 06:18:36 CST 2020, time=2020-06-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1674711, encodeId=fecf16e47113a, content=<a href='/topic/show?id=b1644442913' target=_blank style='color:#2F92EE;'>#头颈部癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44429, encryptionId=b1644442913, topicName=头颈部癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=039a27091165, createdName=wangtianj2016@, createdTime=Mon Apr 19 09:18:36 CST 2021, time=2021-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795207, encodeId=a1411e952073b, content=<a href='/topic/show?id=5cd1169138f' target=_blank style='color:#2F92EE;'>#support#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16913, encryptionId=5cd1169138f, topicName=support)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Fri Feb 05 12:18:36 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289683, encodeId=18a612896833b, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Jun 24 06:18:36 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491866, encodeId=2118149186641, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Wed Jun 24 06:18:36 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589833, encodeId=3e001589833d6, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Wed Jun 24 06:18:36 CST 2020, time=2020-06-24, status=1, ipAttribution=)]
    2020-06-24 wshxjq
  5. [GetPortalCommentsPageByObjectIdResponse(id=1674711, encodeId=fecf16e47113a, content=<a href='/topic/show?id=b1644442913' target=_blank style='color:#2F92EE;'>#头颈部癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44429, encryptionId=b1644442913, topicName=头颈部癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=039a27091165, createdName=wangtianj2016@, createdTime=Mon Apr 19 09:18:36 CST 2021, time=2021-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795207, encodeId=a1411e952073b, content=<a href='/topic/show?id=5cd1169138f' target=_blank style='color:#2F92EE;'>#support#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16913, encryptionId=5cd1169138f, topicName=support)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Fri Feb 05 12:18:36 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289683, encodeId=18a612896833b, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Jun 24 06:18:36 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491866, encodeId=2118149186641, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Wed Jun 24 06:18:36 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589833, encodeId=3e001589833d6, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Wed Jun 24 06:18:36 CST 2020, time=2020-06-24, status=1, ipAttribution=)]

相关威廉亚洲官网

Radiother Oncol:中风险和高风险前列腺癌多中心II期hypo-FLAME试验的主要终点分析

前列腺癌(PCa)放疗后的局部复发常发生在肉眼可见的肿瘤部位。由于PCa细胞对高剂量敏感,低分割全腺体立体定向体放射治疗(SBRT)同时结合前列腺内宏观肿瘤(s)消融微烧蚀可能是降低局部失败风险的一种

2020 ASCO年会:短程放疗为晚期直肠癌患者带来新获益

一年一度的美国临床肿瘤学会(ASCO)年会是全球肿瘤界最具影响力的盛会之一,最前沿的科研成果、肿瘤预防治疗及护理的相关临床数据都会在会上公布。

J Clin Oncol:局部前列腺癌体外放射治疗中加入雄激素阻断治疗或者近距离放射治疗研究

在局部前列腺癌男性中,在体外放射治疗(EBRT)中加入雄激素阻断治疗(ADT)或者近距离放射治疗(BT)能够改善各种肿瘤终点。实践表明那些接受BT的患者不太可能接受ADT,因此,有研究人员进行了元分析

Blood:EGFR依赖性的DNA修复促进造血再生

EGF通过激活DNA-PKcs和NHEJ促进HSC DNA修复和造血再生。 EGF在化疗后驱动造血细胞再生,并在放疗后促进人HSC恢复,同时增加HSC基因间突变

BMC Cancer:根治性前列腺切除术后高危PSA复发的前列腺癌的抢救性放疗加安慰剂与SRT加恩扎鲁胺的II期随机双盲对照研究

在前列腺癌根治性切除术后PSA升高的男性中,抢救性放射治疗(SRT)提供了第二次治愈机会。激素治疗可以与SRT结合使用,以增加对前列腺肿瘤的控制,尽管伴随有更高的治疗副作用率。本试验研究了SRT与激素

Lancet:早期乳腺癌术后1周26Gy放疗方案效果评估

对于早期乳腺癌术后接受局部辅助放疗患者,采用1周以上,5次,总计26Gy的放疗方案对疾病的控制效果与传统的3周以上,15次,总计40Gy放疗方案相当